Nanotechnology: a new immuno-onocology weapon
This article outlines three innovative studies that use nanotechnology to deliver a new immunotherapy approach towards cancers.
List view / Grid view
Articles
Keeping T cells strong and improving cancer immunotherapy
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Silencing the messenger in elevated lipoprotein(a)
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
How to block trogocytosis and improve CAR T-cell therapy
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
A “hot” issue: TGF -β and checkpoint inhibitor resistance
In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…
Drug Target Review Immuno-oncology ebook 2022
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
Drug Target Review Screening ebook 2022
In this ebook are articles on how artificial intelligence can be used to identify drug candidates, data-lead screening models and autonomous strategies for molecular discovery.
Drug Target Review Cell and Gene Therapy Supplement 2022
This supplement focuses on how cell and gene therapy can target diseases such as cancer and reduce elevated lipoprotein(a).
Drug Target Review – Issue 4 2022
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
Five recent CRISPR drug target discoveries
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
Highlights from PEGS Europe’s Protein & Antibody Engineering Summit
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
Drug discovery for COPD treatments
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
Is hydroquinine the answer to antimicrobial resistance?
In this exclusive Q&A, Dr Robert Baldock, Research Scientist at the University of Portsmouth, discusses the compound hydroquinine and how it could be used as an effective weapon against a pathogen that causes serious infections in humans, mostly hospital patients.
How ageing triggers Huntington’s disease
A new study found that as patients age, Huntington’s disease gradually impairs the important cellular housekeeping process autophagy, which is responsible for eliminating waste from cells.
Developing novel genome editing tools
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.